A detailed history of Jpmorgan Chase & CO transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 3,001,397 shares of TSHA stock, worth $5.55 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,001,397
Previous 2,963,553 1.28%
Holding current value
$5.55 Million
Previous $6.64 Million 9.13%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$2.01 - $2.46 $76,066 - $93,096
37,844 Added 1.28%
3,001,397 $6.03 Million
Q2 2024

Aug 12, 2024

BUY
$2.04 - $4.17 $5.85 Million - $12 Million
2,869,812 Added 3061.43%
2,963,553 $6.64 Million
Q1 2024

May 10, 2024

BUY
$1.43 - $3.25 $81,877 - $186,085
57,257 Added 156.94%
93,741 $269,000
Q4 2023

Feb 12, 2024

BUY
$1.33 - $2.88 $48,341 - $104,679
36,347 Added 26530.66%
36,484 $64,000
Q3 2023

Nov 14, 2023

SELL
$0.63 - $3.66 $1,036 - $6,020
-1,645 Reduced 92.31%
137 $0
Q4 2022

Feb 13, 2023

SELL
$1.39 - $2.98 $59,458 - $127,472
-42,776 Reduced 96.0%
1,782 $4,000
Q3 2022

Nov 14, 2022

SELL
$1.76 - $4.94 $413,130 - $1.16 Million
-234,733 Reduced 84.05%
44,558 $86,000
Q2 2022

Aug 11, 2022

SELL
$2.47 - $6.77 $396,467 - $1.09 Million
-160,513 Reduced 36.5%
279,291 $1.04 Million
Q1 2022

May 11, 2022

BUY
$5.22 - $11.86 $1.06 Million - $2.4 Million
202,245 Added 85.13%
439,804 $2.87 Million
Q4 2021

Feb 10, 2022

SELL
$11.43 - $19.2 $2.09 Million - $3.51 Million
-182,803 Reduced 43.49%
237,559 $2.77 Million
Q3 2021

Nov 12, 2021

BUY
$15.82 - $21.57 $6.65 Million - $9.07 Million
420,362 New
420,362 $7.83 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $89.5M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.